126 related articles for article (PubMed ID: 35570167)
21. Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.
Elosua-Gonzalez M; Lopez-Estebaranz JL; Garcia-Zamora E; Vela-Ganuza M; Rodrigez-Vasquez X
Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677858
[TBL] [Abstract][Full Text] [Related]
22. RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
Kaya G; Saxer-Sekulic N; Kaya A; Sorg O; Boespflug A; Thomas L; Saurat JH
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1368-1372. PubMed ID: 29575357
[TBL] [Abstract][Full Text] [Related]
23. Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib.
Tsuboi S; Yoshino K; Yamaguchi K; Imafuku K; Ohara K
J Dermatol; 2017 May; 44(5):607-608. PubMed ID: 27334634
[No Abstract] [Full Text] [Related]
24. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
25. [Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
Boiché M; Conart JB; Angioi-Duprez K
J Fr Ophtalmol; 2018 Jun; 41(6):e291-e292. PubMed ID: 29908650
[No Abstract] [Full Text] [Related]
26. Central retinal vein occlusion associated with vemurafenib use in metastatic skin melanoma.
Yang SY; Chen SN
Kaohsiung J Med Sci; 2018 Sep; 34(9):535-536. PubMed ID: 30173784
[No Abstract] [Full Text] [Related]
27. Dabrafenib and trametinib combination therapy safely performed in a patient with metastatic melanoma after severe liver toxicity due to vemurafenib.
Shimada S; Fukushima S; Niimori D; Miyashita A; Setoyama H; Sasaki Y; Ihn H
J Dermatol; 2018 Jun; 45(6):e157-e158. PubMed ID: 29315749
[No Abstract] [Full Text] [Related]
28. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib-induced DRESS/DIHS resulting in spontaneous melanoma regression: an immunological reaction shedding new light on melanoma treatment?
Olteanu C; Scope A; Steinberg-Silman Y; Ziv M; Shear NH; Dodiuk-Gad RP; Markel G
Int J Dermatol; 2020 May; 59(5):e139-e141. PubMed ID: 32212333
[No Abstract] [Full Text] [Related]
30. ACUTE EXUDATIVE PARANEOPLASTIC POLYMORPHOUS VITELLIFORM MACULOPATHY DURING VEMURAFENIB AND PEMBROLIZUMAB TREATMENT FOR METASTATIC MELANOMA.
Sandhu HS; Kolomeyer AM; Lau MK; Shields CL; Schuchter LM; Nichols CW; Aleman TS
Retin Cases Brief Rep; 2019 Spring; 13(2):103-107. PubMed ID: 28614138
[TBL] [Abstract][Full Text] [Related]
31. Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma.
Kato J; Hida T; Kamiya T; Sato S; Takahashi H; Torigoe T; Uhara H
JAMA Dermatol; 2018 May; 154(5):621-622. PubMed ID: 29590278
[No Abstract] [Full Text] [Related]
32. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
[No Abstract] [Full Text] [Related]
33. Vemurafenib-induced bilateral facial palsy.
Shailesh FN; Singh M; Tiwari U; Hutchins LF
J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
[TBL] [Abstract][Full Text] [Related]
34. [Bilateral uveitis associated with protein kinase inhibitor-based treatment of skin melanoma (case study)].
Udovichenko EV; Danilova LP; Sorokin EL; Fil AA
Vestn Oftalmol; 2023; 139(3):69-75. PubMed ID: 37379111
[TBL] [Abstract][Full Text] [Related]
35. Decreased photosensitivity to UVA on vemurafenib combined with cobimetinib.
Frenard C; Dutartre H; Boisrobert A; Khammari A; Dreno B
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):e87-e88. PubMed ID: 30198584
[No Abstract] [Full Text] [Related]
36. Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma.
Velter C; Libenciuc C; Routier E; Mateus C; Fahmy J; Ghoufi L; Lambotte O; Not A; Cauquil C; Claveau S; Claveau J; Robert C
Eur J Cancer; 2019 Apr; 111():8-11. PubMed ID: 30798086
[No Abstract] [Full Text] [Related]
37. NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib.
Parekh V; Sobanko J; Miller CJ; Karakousis G; Xu W; Letrero R; Elenitsas R; Xu X; Elder DE; Amaravadi R; Schuchter LM; Nathanson KL; Wilson MA; Chu EY
J Cutan Pathol; 2019 Mar; 46(3):190-194. PubMed ID: 30552700
[TBL] [Abstract][Full Text] [Related]
38. Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Furudate S; Fujimura T; Kambayashi Y; Hidaka T; Sato Y; Tanita K; Hashimoto A; Aiba S
J Dermatol; 2017 Sep; 44(9):e226-e227. PubMed ID: 28439948
[No Abstract] [Full Text] [Related]
39. Reversible BRAF inhibitor-induced acute exudative paraneoplastic polymorphous vitelliform maculopathy.
Samalia P; Niederer R
N Z Med J; 2021 Aug; 134(1540):89-92. PubMed ID: 34482393
[No Abstract] [Full Text] [Related]
40. Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma.
Chen P; Chen F; Zhou B
Clin Exp Dermatol; 2019 Apr; 44(3):243-251. PubMed ID: 30280426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]